Calprotectin in acute infections and sepsis for prognosis, characterisation and diagnosis in the ED

08. Jun 2023 | 4 min read

Calprotectin in acute infections and sepsis for prognosis, characterisation and diagnosis in the ED

Calprotectin in the Emergency Department (ED)

We are pleased to present results from a prospective clinical trial in collaboration with Charité – Universitätsmedizin Berlin and Labor Berlin.  The results from the prospective CASCADE-trial (Calprotectin in acute infections and sepsis for prognosis, characterisation and diagnosis in the ED) were presented at the Innovation Theatre at ECCMID by the PI of the trial Dr. Wolfgang Bauer.

Gentian's plasma and serum calprotectin immunoassay GCAL® was used in the trial and showed high performance for detection of bacterial infection and prediction of sepsis and mortality. In conclusion calprotectin is a promising biomarker for detection of bacterial infection and sepsis, can be used for estimation of disease severity and guide clinical care and treatment decisions in the emergency department  setting.


Watch the presentation now

In his presentation Dr. Bauer discusses the value of calprotectin for diagnosis and management of acute infections and sepsis in the ED.

 

 

Calprotectin advantages

Studies have shown the ability of calprotectin to predict bacterial infections before onset of clinical symptoms and distinguish between bacterial and viral infections, with high sensitivity and specificity. With early diagnosis of bacterial infections delayed treatment will be avoided as well as deterioration due to severe infections, including sepsis1-3.

 

blood calprotectin

 

Get in touch for more information and validation opportunities

Are you interested in adding GCAL® to your test menu, distribution or to discuss OEM opportunities for your company? Please fill out the form below or send us an email to marketing@gentian.com.

 

 

 

References: 

  1. Lipcsey M et al. The time course of calprotectin liberation from human neutrophil granulocytes after Escherichia coli and endotoxin challengeInnate Immun. 2019;25(6):369-373
  2. Jonsson N et al. Calprotectin as an early biomarker of bacterial infections in critically ill patients: an exploratory cohort assessmentCrit Care Resusc. 2017;19(3):205-213
  3. Fullerton J et al. Kinetics of calprotectin, procalcitonin and C-reactive protein in healthy volunteers administered intravenous endotoxin. 40th International Symposium on Intensive Care & Emergency Medicine. Critical Care. 2020. P474

You may also read


GCAL® Customer Interview: Calprotectin in routine care across departments

Mar 30, 2026

GCAL® Customer Interview: Calprotectin in routine care across departments

From laboratory integration to clinical impact at Motol University Hospital Inflammation is rarely..

GCAL® Customer Story - 24/7 calprotectin testing in acute and chronic care

Mar 27, 2026

GCAL® Customer Story - 24/7 calprotectin testing in acute and chronic care

Enabling 24/7 circulating calprotectin testing in clinical practice

Calprotectin as a biomarker for immune dysfunction and 28‑day mortality in sepsis

Mar 26, 2026

Calprotectin as a biomarker for immune dysfunction and 28‑day mortality in sepsis

Circulating calprotectin: biomarker of immune dysfunction in sepsis - study results Results from a post-hoc..